Akari Therapeutics (AKTX) Amortization - Intangibles (2015)

Akari Therapeutics' (AKTX) quarterly Amortization - Intangibles came in at $19.3 million in Q3 2015.

Akari Therapeutics (AKTX) Amortization - Intangibles (2015) Analysis & Trends

Akari Therapeutics has disclosed Amortization - Intangibles across 1 years of filings, most recently posting $19.3 million for Q3 2015.

Amortization - Intangibles for Q3 2015 came in at $19.3 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2015 was $19.3 million (changed N/A YoY), and the FY2015 annual result was $19.3 million, changed N/A from the prior year.
Amortization - Intangibles came in at $19.3 million for Q3 2015 at Akari Therapeutics.
In the past five years, Amortization - Intangibles ranged from a high of $19.3 million in Q3 2015 to a low of $19.3 million in Q3 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Regeneron Pharmaceuticals	63.43 Bn	54.67 Bn	3.31 Bn

Download Data

Date	Value
Sep 30, 2015	19.28 Mn